Dr Martens, a renowned boot manufacturer, anticipates facing significant financial losses due to US tariffs this year. The company, known for its iconic yellow-stitched boots, has disclosed that the majority of its footwear production now takes place in Vietnam, which has incurred elevated import duties as a consequence of the trade war initiated by US President Donald Trump.
Having relocated its manufacturing operations from China to mitigate US import tariffs, Dr Martens announced that it is prepared for a substantial impact on full-year profits, estimating a multimillion-pound setback. Despite this challenge, the company remains confident in achieving its forecasted underlying pre-tax profits ranging from £53 million to £60 million for the year.
In response to the tariff implications, Dr Martens plans to counterbalance the additional costs starting from the following fiscal year. The firm is committed to managing the impact of increased tariffs beyond 2026/27 by implementing stringent cost controls, adjusting product sourcing strategies, and revising pricing policies in the US market.
The company’s latest update on tariffs coincided with the release of its half-year financial results, which revealed a reduction in losses to £11 million for the period ending on September 28. Notably, sales for the first half increased by 0.8% to £327.3 million, indicating a positive trend for the brand.
Ije Nwokorie, CEO of Dr Martens, expressed satisfaction with the progress made by the company, highlighting a notable surge in shoe volumes and successful product launches. Despite market uncertainties and consumer cautiousness, the company remains optimistic about its strategies and prospects for the year.
Commenting on the financial performance, Russ Mould, investment director at broker AJ Bell, acknowledged the gradual improvements being made by Dr Martens in its journey towards profitability. While the company’s turnaround efforts are underway, Mould emphasized that the recovery process may be gradual rather than instantaneous, noting some positive indicators in the half-year results.
Although the market response to the financial figures was not overwhelmingly positive, with a decline in the company’s share price during early trading, Dr Martens is optimistic about its future outlook and remains focused on implementing effective measures to navigate the challenges posed by tariffs and market dynamics.